Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 and Selumetinib in Advanced Cancers
NCT02583542Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Jun 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vistusertib in triple-negative breast cancer (TNBC), squamous cell carcinoma of the lung (LSCC), non-small cell lung cancer (NSCLC), solid tumor, sponsored by Queen Mary University of London. Status: unknown.
02
Drugs
vistusertib
03
Conditions
triple-negative breast cancer (TNBC)squamous cell carcinoma of the lung (LSCC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT02583542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583542.